GLP-1 Medications for Menopause and Other Special Populations

Weight gain around menopause is common. As estrogen levels fall, metabolism tends to slow and body fat often shifts toward the abdomen, even when diet and activity habits stay the same.

GLP-1 receptor agonists are a class of medications used for type 2 diabetes and chronic weight management. The most widely used options include semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). Rather than acting as simple appetite suppressants, these drugs mimic a gut hormone that reduces hunger signals, slows the rate of digestion, and helps the body regulate blood sugar. That combination addresses several of the metabolic changes associated with menopause, which is why the class is frequently discussed for this group. The clinical data below is provided as general information to support an informed conversation with a licensed clinician, not as medical advice or a treatment recommendation.

FindDrugs.org is an independent research organization. Its content is based on primary sources, including FDA prescribing information and peer-reviewed clinical outcomes data. It does not accept funding for product promotion and refers all treatment decisions to licensed clinicians.

GLP-1 Medications and Menopausal Weight Management

Clinical Results Across Menopausal Stages

A 2025 post-hoc analysis of the SURMOUNT tirzepatide program, published in the journal Obesity, examined weight change by reproductive stage. In the SURMOUNT-1 population, tirzepatide was associated with mean weight reductions of about 26% in premenopausal women, 23% in perimenopausal women, and 23% in postmenopausal women, compared with roughly 2 to 3% in the placebo groups. These figures are consistent with the overall SURMOUNT-1 result reported in the New England Journal of Medicine, in which tirzepatide 15 mg reduced body weight by about 20.9% versus 3.1% for placebo at 72 weeks.

The same post-hoc analysis reported waist-circumference reductions of about 22 cm in premenopausal women and about 20 cm in perimenopausal and postmenopausal women, compared with about 4 to 5 cm in the placebo groups, a measure of reduced abdominal fat. Among participants with a baseline body mass index under 35, between 30% and 52% of women across the reproductive-stage subgroups reached a waist-to-height ratio of 0.49 or lower with tirzepatide.

Abdominal fat appears to respond particularly well to this drug class.

Combining GLP-1 Treatment With Hormone Therapy

Some research has examined GLP-1 medications used alongside menopausal hormone therapy. A 2024 retrospective cohort study in the journal Menopause reported that postmenopausal women taking semaglutide together with hormone therapy lost more weight than those taking semaglutide without it at 3, 6, 9, and 12 months. The hormone-therapy group was small — 16 women, compared with 90 not using it — and the study's authors call for larger studies to confirm the finding.

These are observational findings, not treatment recommendations. Whether hormone therapy is appropriate for any individual, and whether it should be combined with a GLP-1 medication, is a decision for that person and their clinician.

Safety, Side Effects and Contraindications

GLP-1 receptor agonists carry specific safety considerations that a clinician should review before treatment begins. Understanding them supports a more informed discussion with a healthcare provider.

Bone-density screening before and during treatment, coordinated care between primary care and gynecology, resistance training, and adequate protein intake are among the topics a postmenopausal patient may wish to raise with their clinicians.

Considerations for PCOS, Men, and People With Diabetes

GLP-1 receptor agonists are discussed across several groups beyond postmenopausal women, and the reasons clinical supervision matters vary by population.

• PCOS: GLP-1 medications can improve insulin sensitivity, and polycystic ovary syndrome frequently involves insulin resistance. Using GLP-1 drugs specifically for PCOS is off-label, and whether they are appropriate for any individual is a clinical judgment.
• Men: Men can achieve meaningful weight loss with comprehensive treatment that combines diet, activity, and medication when a clinician considers it appropriate.
• People with diabetes: Several GLP-1 agents are FDA-approved to improve blood-sugar control in type 2 diabetes. It is worth being precise about the approvals: Byetta (exenatide) and Victoza (liraglutide) are approved for glycemic control in type 2 diabetes, not for weight management. The FDA-approved weight-management medications in this class are separate products, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). Exenatide, derived from a compound in the Gila monster's saliva, was the first GLP-1 receptor agonist approved by the FDA.

What to Ask Your Clinician

Starting GLP-1 therapy during menopause raises questions about hormonal interactions, bone health, and muscle preservation. The questions below cover topics a patient may want to raise before and during treatment.

Hormone Therapy and Medication Interactions

1. Whether switching from oral to transdermal estrogen makes sense, since GLP-1 medications may affect how the body absorbs oral hormones.
2. Backup contraception options if perimenopausal and taking oral contraceptives alongside GLP-1 therapy, since absorption changes may affect contraceptive reliability.
3. Whether combining hormone therapy with a GLP-1 medication could affect both weight and vasomotor symptoms such as hot flashes.
4. Absorption considerations with oral micronized progesterone used for endometrial protection, where data on this specific combination is limited.
5. Whether the clinician has training in menopause care and menopause-specific weight management.

Monitoring, Lifestyle, and Side Effects

6. Guidance on protein intake targets to help preserve muscle mass during weight loss.
7. How often resistance training is recommended for maintaining muscle while on these medications.
8. Whether monitoring tools such as DEXA scans or body-composition assessments should be used to track fat and muscle separately.
9. How these medications may affect bone health, especially if osteoporosis risk factors are present.
10. Side effects specific to this stage of life, including how nausea or appetite changes may interact with hot flashes or other symptoms.

Frequently Asked Questions

Does GLP-1 medication work at every stage of menopause?

Published trial data suggests GLP-1 receptor agonists are effective across premenopause, perimenopause, and postmenopause, though individual results vary with factors such as insulin resistance, central adiposity, and metabolism. Abdominal fat appears to respond particularly well to these medications.

What happens if someone discontinues GLP-1 therapy?

Discontinuing GLP-1 medications is generally associated with weight regain. In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost in the year after stopping semaglutide, and cardiometabolic improvements moved back toward baseline. Beyond weight management, GLP-1 drugs have FDA-approved or trial-supported roles in cardiovascular risk reduction and obstructive sleep apnea. People with type 2 diabetes or PCOS may have additional reasons to plan discontinuation carefully with a clinician, since these medications also affect insulin resistance and blood-sugar control.

How does menopause affect weight gain?

Menopause involves hormonal shifts that tend to slow metabolic rate, which can make weight gain more likely even when eating habits stay consistent. Weight-management medications are one tool a clinician may discuss as part of a broader plan.

Can GLP-1 medications help with PCOS?

GLP-1 receptor agonists can improve insulin sensitivity and support weight loss, which is relevant because polycystic ovary syndrome frequently involves insulin resistance. Using these medications specifically for PCOS is off-label, so appropriateness is a clinical decision made with a healthcare provider.

Can men benefit from GLP-1 treatment for weight?

Men can respond well to structured obesity treatment that addresses diet, activity, and medication when a clinician considers it appropriate. As with any population, the medication works best alongside lifestyle changes.

Are GLP-1 medications approved for weight management in people with diabetes?

Some are, and some are not. Byetta (exenatide) and Victoza (liraglutide) are FDA-approved to improve blood-sugar control in type 2 diabetes, not for weight management. The weight-management approvals in this class belong to separate products such as Saxenda, Wegovy, and Zepbound. A clinician can advise which medication, if any, fits a given situation.

Where can patients find reliable information about GLP-1 medications?

DailyMed, operated by the National Library of Medicine, is the most direct source for complete FDA-approved drug labeling, and peer-reviewed studies are available through pmc.ncbi.nlm.nih.gov. FindDrugs.org bases its content on verifiable sources, maintains neutrality on branded and compounded medications, and refers all treatment decisions to licensed clinicians.